Pirtobrutinib (CAS 2101700-15-4): A Potent Non-Covalent BTK Inhibitor for B-Cell Malignancies
Explore Pirtobrutinib, a leading non-covalent BTK inhibitor for B-cell malignancies. Discover its mechanism, applications, and benefits. We are a trusted Pirtobrutinib supplier in China.
Get a Quote & SampleUnlock Advanced Cancer Therapies with Pirtobrutinib
Pirtobrutinib
As a premier Pirtobrutinib manufacturer and supplier in China, we provide high-purity Pirtobrutinib (CAS 2101700-15-4) for pharmaceutical research and development. Our commitment to quality ensures that you receive a reliable BTK inhibitor for your critical projects, offering competitive pricing and efficient supply chain solutions.
- Discover the efficacy of Pirtobrutinib as a potent BTK inhibitor for B-cell malignancies
- Learn about its advantages in overcoming covalent BTK inhibitor resistance
- Source high-quality Pirtobrutinib from a trusted China supplier for your R&D needs
- Inquire about Pirtobrutinib price and availability for purchase
Key Advantages of Pirtobrutinib
Overcoming Treatment Resistance
Pirtobrutinib is a next-generation BTK inhibitor designed to overcome resistance mechanisms, including C481 mutations, that limit the efficacy of covalent inhibitors. This makes it a vital pharmaceutical intermediate for treating refractory B-cell malignancies.
High Selectivity and Potency
With nanomolar potency against wild-type and mutant BTK, Pirtobrutinib exhibits over 300-fold selectivity for BTK compared to other kinases. This targeted action minimizes off-target effects, making it an ideal compound for research and potential therapeutic development.
Broad Applicability in Oncology
Pirtobrutinib demonstrates promising efficacy in various B-cell lymphomas, including mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). As a key pharmaceutical intermediate, it supports the development of advanced cancer treatments.
Applications of Pirtobrutinib
Mantle Cell Lymphoma (MCL) Treatment
Pirtobrutinib is approved for adult patients with relapsed or refractory MCL. Our high-quality product is available for purchase by manufacturers seeking reliable pharmaceutical intermediates.
Chronic Lymphocytic Leukemia (CLL/SLL) Therapy
The compound is also indicated for adult patients with relapsed or refractory CLL/SLL. Seek a reliable Pirtobrutinib supplier in China for your research and manufacturing needs.
Overcoming BTK Inhibitor Resistance
Its non-covalent binding mode allows Pirtobrutinib to maintain efficacy even with high BTK turnover rates, addressing a key limitation of earlier BTK inhibitors and making it a valuable pharmaceutical intermediate for next-generation therapies.
Research and Development
As a potent BTK inhibitor, Pirtobrutinib is crucial for preclinical and clinical research in oncology. Contact us to buy Pirtobrutinib and secure your supply from a reputable manufacturer.